Filtering by:
FDAFDA Approves Libtayo (Cemiplimab) for a Type of Skin Cancer
The US Food and Drug Administration (FDA) has approved Libtayo (cemiplimab) to treat people with advanced squamous cell carcinoma of the skin.
FDA Approves Lumoxiti (Moxetumomab Pasudotox) for Hairy Cell Leukemia
The US Food and Drug Administration (FDA) has approved Lumoxiti (moxetumomab pasudotox-tdfk) for adults with hairy cell leukemia (HCL) that did not get better with at least 2 different previous treatments or got better but then came back.
FDA Approves Opdivo (Nivolumab) for Small Cell Lung Cancer
The US Food and Drug Administration had approved the immunotherapy drug Opdivo (nivolumab) to treat people with small cell lung cancer (SCLC).
FDA Approves Poteligeo (Mogamulizumab) for Lymphoma of the Skin
The US Food and Drug Administration (FDA) has approved Poteligeo (mogamulizumab) to treat people with some types of skin lymphoma.
FDA Approves Azedra (Iobenguane) for Rare Adrenal Tumors
The US Food and Drug Administration has approved the radiotherapy drug Azedra (iobenguane I-131) to treat some adults and adolescents ages 12 and older with rare tumors of the adrenal gland called pheochromocytomas, as well as for similar tumors outside of the adrenals, called paragangliomas.
FDA Approves Tibsovo (Ivosidenib) for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved the targeted therapy drug Tibsovo (ivosidenib) to treat some adults with a certain type of acute myeloid leukemia (AML).
FDA Approves Drug Combination for Aggressive Type of Thyroid Cancer
The US Food and Drug Administration (FDA) has approved a combination of 2 targeted drugs to treat people with anaplastic thyroid cancer that has a certain type of gene mutation (BRAF V600E) and cannot be completely removed through surgery.
FDA Approves Consumer Test for Certain BRCA Mutations
The US Food and Drug Administration (FDA) has approved the first direct-to-consumer tests for certain BRCA1 and BRCA2 gene mutations.
